baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

CRISPR Therapeutics AG/ CH0334081137 /

2024-04-25 9:59:59 PM	Chg. -1.90	Volume	Bid-	Ask-	Market Capitalization	Dividend Y.	P/E Ratio
53.76USD	-3.41%	31,911 Turnover: 1.7 mill.	-Bid Size: -	-Ask Size: -	4.31 bill.USD	-	-

GlobeNewswire 04-23 Aspen Ideas: Health Announces Global Health Experts to Speak at Annual Summit

GlobeNewswire 04-22 CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASG...

GlobeNewswire 04-08 TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H.,...

GlobeNewswire 04-03 CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

GlobeNewswire 04-03 ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

GlobeNewswire 04-01 CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Me...

GlobeNewswire 03-13 CRISPR Therapeutics Proposes New Appointment to the Board of Directors

GlobeNewswire 02-21 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial...

GlobeNewswire 02-15 CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

GlobeNewswire 02-13 CRISPR Therapeutics Announces $280 Million Registered Direct Offering

GlobeNewswire 02-13 European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemc...

GlobeNewswire 01-16 CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamgl...

GlobeNewswire 01-03 CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

TeleTrader 2023-12-08 US FDA approves first gene editing treatment

GlobeNewswire 2023-12-04 CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Dise...

GlobeNewswire 2023-12-02 CASGEVY Gets Bahrain approval for treatment, marking it second country in the world

GlobeNewswire 2023-11-06 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

GlobeNewswire 2023-11-06 CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Se...

GlobeNewswire 2023-10-31 CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotem...

GlobeNewswire 2023-10-31 CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Applica...

GlobeNewswire 2023-10-16 CRISPR Therapeutics Proposes New Appointment to the Board of Directors

GlobeNewswire 2023-09-27 CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

GlobeNewswire 2023-09-07 CRISPR Therapeutics Announces Leadership Transition

GlobeNewswire 2023-08-30 CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference

CRISPR Therapeutics AG/ CH0334081137 /

If you wish to receive reply to your feedback, please provide your email address.